Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Neutral)

Key Terms

glp-1 medication medical

A GLP-1 medication is a type of drug that mimics a natural gut hormone (glucagon-like peptide-1) to lower blood sugar and often reduce appetite and body weight; think of it as a thermostat that helps the body regulate glucose and hunger. It matters to investors because strong demand, pricing, regulatory approvals, patent status and manufacturing capacity for these medicines can drive sales growth, corporate valuations and sector-wide competition.

03/11/2026 - 09:00 AM

First shipments expected in April

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced that it has officially begun training and on‑boarding partner accounts across the United States, including large academic medical centers and private practices. The company has begun manufacturing FDA-approved product and expects to begin shipping in April. This milestone represents a pivotal step in the company’s commercial expansion into the world’s largest markets for obesity treatment, where an estimated 20 million Americans have already started and stopped a GLP-1 medication, which presents an immediately accessible target market.¹

In addition, as part of its U.S. launch strategy, Allurion is actively exploring partnerships with self-insured employers—an important channel through which a large portion of Americans receive healthcare coverage. These partnerships have the potential to significantly broaden access to the Allurion Program by enabling benefit coverage for eligible employees and their families. An estimated 165 million Americans are covered through their employers, and 10.5% of employer insurance claims are related to GLP-1 medications, leading to approximately $30 billion in annual expenditure related to GLP-1s.²

“We believe Allurion has a unique opportunity to fill an important gap in the U.S. market with a solution that is clinically proven, accessible, and can seamlessly integrate into existing practices,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “In just the first weeks of engaging with customers and partners across the country, the feedback has been overwhelmingly positive. Providers are excited about offering their patients a proven, noninvasive weight loss therapy either as an alternative or complement to their GLP-1 medications. This early momentum reinforces our belief that Allurion can make a meaningful impact in the lives of millions of Americans.”

With more than 100 million Americans with obesity and the demand for nonsurgical, nonpharmaceutical weight management options continuing to grow, we believe Allurion’s entry into the market represents a significant opportunity to transform care delivery and expand access to safe and effective treatment options. The company expects U.S. availability to accelerate throughout 2026 as additional partners complete training and begin offering the Allurion Program in clinical settings nationwide.

About Allurion

Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the FDA PMA approved Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers featuring the Iris AI platform, Allurion Insights for healthcare providers, and the Allurion Connected Scale.

In the United States, the Allurion Gastric Balloon System (AGBS) is indicated to promote short-term limited weight loss in adult individuals with obesity between the ages of 22 years and 65 years with a body mass index (BMI) ≥ 30 kg/m² and ≤ 40 kg/m² who have had at least one unsuccessful attempt at a weight loss program. The residence time for each balloon is variable with an average observed residence time of 15.3 weeks. The AGBS is to be used in conjunction with a moderate intensity lifestyle modification therapy program. The AGBS consists of up to two Allurion Balloons placed during a 10-month period.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release contains forward-looking statements that reflect Allurion’s beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

Forward-looking statements in this press release include, but are not limited to, statements regarding: the AGBS’s ability to fill a gap in the U.S. obesity market and transform care delivery and expand access to safe and effective treatment options in the U.S.; expectations relating to the acceleration of availability to the AGBS(including in combination with GLP-1 therapies) to treat obesity, including with respect to its therapeutic benefits and the acceptance of Allurion’s products in the marketplace; pioneering in, and providing more patients and providers access to, metabolically healthy weight loss; and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to management.

Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Gastric Balloon System, including the Allurion Smart Capsule; the timing of, and results from, Allurion’s clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Smart Capsule; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading “Risk Factors” in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2025, and as amended on August 19, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on November 17, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.

_______________________

¹ New England Consulting Group. Data on file.

² Allurion estimates. Data on file.